Introduction
Nasopharyngeal carcinoma (NPC) is one of the most common malignant neoplasms in southern China -the incidence in Guangdong Province is about 100-fold higher compared to Europe and North America. Some susceptibility loci and oncogenes have been demonstrated to promote or suppress NPC progression, and in the past few decades, they have been found to serve as prognostic factors and therapy targets; for example, TNFRSF19, CDKN2A-CDKN2B, and MDS1-EVI1 are some newly identified susceptibility loci.
1 BMI1 is a new oncogene for NPC and promotes epithelial-mesenchymal transition (EMT) Mechanistic analyses have found that it binds to tumor suppressor PTEN directly and inhibits its activity to activate PI3K/Akt/GSK-3β signaling pathway. This signaling can increase the stability of Snail that facilitates EMT. Snail also suppresses PTEN expression, PTEN, and PI3K/Akt/GSK-3β and forms a positive feedback loop. 2 But the regulatory mechanism of the development and progression of NPC has not been understood well, and hence the survival of patients with NPC is still poor. However, early diagnosis is critical for NPC treatment and identification of useful biomarkers is essential for NPC prognosis.
URG4, a novel oncogene, promotes the progression of various tumors. For example, it is a natural product of hepatitis B × antigen (HB×Ag), which participates in submit your manuscript | www.dovepress.com
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3 URG4 is upregulated in hepatocellular carcinoma (HCC) tissues. Statistical analyses suggest that its expression is significantly correlated with clinical stages and poor survival of HCC patients. Functional analyses have found that URG4 not only activates Akt signaling pathway, and suppresses cell cycle inhibitors p27 and p21 to promote cell proliferation, 4, 5 but also activates NF-κB pathway to facilitate angiogenesis. 6 URG4 expression is higher in ovarian cancer tissues and hence can serve as a new prognostic marker for ovarian cancer. 7, 8 Apart from HCC and ovarian cancer, URG4 also plays critical roles in gastric cancer, 9 bladder cancer, 10 glioblastoma multiforme, 11 non-smalllung cancer, 12 medullary thyroid cancer, 13 neuroblastoma, 14 prostate cancer, 15 and leukemia. 16 But the role of URG4 in NPC has not been reported yet.
In this study, we determined URG4 expression in NPC tissues and adjacent normal nasopharyngeal tissues and analyzed the relationship between URG4 expression and various clinicopathologic characteristics. Finally we used Cox-regression analysis to evaluate whether URG4 can serve as a prognostic marker for NPC patients.
Materials and methods
Patients and tissue specimens
A total of 102 paraffin-embedded NPC samples were histopathologically diagnosed in 1998-2003 at the Guangzhou First People's Hospital, Guangzhou Medical University, Guangdong, People's Republic of China. These clinical materials were used for research purposes after obtaining patient's written consent. This study was approved by the Institutional Research Ethics Committee of the Guangzhou First People's Hospital. Clinicopathological information of these samples is shown in Table 1 . The clinical stages of all patients were defined according to the Chinese 1992 staging system. 17 Five NPC specimens (T) and adjacent normal nasopharyngeal specimens were also obtained from the Guangzhou First People's Hospital, Guangzhou Medical University. These samples were embedded using paraffin and were stored at 4°C until use.
Immunohistochemistry
Immunohistochemistry (IHC) was performed according to the previously described method by Cao et al. 18 Briefly, all paraffinembedded specimens were cut into 4 µm sections and deparaffinized with xylenes. They were then rehydrated with graded ethanol to distilled water. Antigen retrieval was performed by submerging sections into ethylene diamine tetraacetic acid buffer (pH 8.0) and heating in a microwave oven. A total of 0.3% H 2 O 2 was used to treat sections for 15 minutes to block endo genous peroxidase after being heated, and then the sections were incubated with 1% bovine serum albumin to block nonspecific binding and then incubated with anti-URG4 antibody (1:150, HPA020134, Sigma-Aldrich Co., St Louis, MO, USA) overnight at 4°C. After washing with phosphate-buffered saline, the sections were incubated with biotinylated secondary antibody, followed by further incubation with streptavidinhorseradish peroxidase at 37°C for 30 minutes. The sections were immersed in 3,3′-diaminobenzidine for 10 minutes and counterstained with 10% Mayer's hematoxylin, dehydrated, and mounted in crystal mount. For negative controls, the primary antibody was replaced by normal goat serum.
The results of staining were scored independently by three pathologists blinded to clinical outcome according to the proportion of positively stained tumor cells and the intensity of staining. The proportion of positively stained tumor cells was scored as follows: 0 (no positive tumor cells), 1 (,20% positive tumor cells), 2 (20%-50% positive tumor cells), 3 (50%-80% positive tumor cells), and 4 (.80% positive tumor cells). The intensity of staining was graded as follows: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown). The staining index (SI) was calculated as the product 
Results
Urg4 is upregulated in nPc tissues
To investigate the role of URG4 in NPC, we determined the expression of URG4 in the NPC tissues and adjacent normal nasopharyngeal tissues of five patients by IHC. We found that URG4 was expressed only in primary NPC tissues and no specific URG4 staining was observed in adjacent normal nasopharyngeal tissues (Figure 1 ). These suggested that URG4 was upregulated in NPC tissues.
Urg4 expression is positively correlated with clinical aggressiveness of nPc
We determined URG4 expression in 102 paraffin-embedded archival NPC tissues using IHC. (Table 2 ). We also found that URG4 was mainly located in cytomembrane (Figure 2 (Figure 2) . We analyzed the association between URG4 expression and the patient's clinicopathologic characteristics. As shown in Table 3 , we found that URG4 expression was significantly correlated with clinical stage, larger tumor size (T classification), and lymph node involvement (N classification). But whether URG4 expression was significantly correlated with distant metastasis (M classification) is not clear because different P-values were calculated according to different statistical methods (P=0.036 using chi-square test and P=0.067 using Fisher's exact test). However, there was no significant correlation between URG4 expression, sex, and age. We further analyzed the correlation between URG4 expression and clinical stage, larger tumor size, lymph node involvement, and distant metastasis using Spearman's correlation analysis and found that URG4 expression was positively correlated with these clinicopathologic characteristics ( Table 4 ). We investigated the correlation between URG4 expression and patient's survival using Kaplan-Meier analysis with the log-rank test. We found that URG4 expression was significantly negatively correlated with the overall survival of NPC patients, patients with low expression of URG4 had better outcome, and patients with high expression of URG4 had poor survival ( Figure 3) .
We used univariate Cox-regression analysis to determine the clinical significance of various prognostic factors that might influence the survival and tumor progression in NPC patients. The results showed that clinical stage, T classification, and URG4 expression were significant poor prognostic factors. Multivariate Cox-regression analysis revealed that clinical stage, T classification, and URG4 expression were independent prognostic factors for patients with NPC (Table 5) . Thus, these results suggested that URG4 expression has a significant correlation with the prognosis of NPC and could serve as a biomarker for the prognosis of NPC patients.
Discussion
In this study, we found that URG4 was overexpressed in NPC tissues and its expression was positively correlated with advancing clinical stage. Statistical analysis revealed that URG4 expression significantly correlated with NPC progression and patients with high URG4 expression had poor clinical outcome. Therefore, it can function as an unfavorable prognostic factor.
New valuable prognostic factors are important to develop novel therapeutic strategies. Recently, many prognostic factors, such as centromere protein H (CENP-H) 17 and MMP9, 19 have been found. To estimate cancer progression and the outcomes of NPC patients, more biomarkers have to be discovered. We used a cohort of 102 patients' samples to determine the relationship between URG4 expression and patient survival. We found that patients with high URG4 expression had poor survival. To demonstrate whether URG4 could serve as an indicator of NPC progression, we analyzed the correlation between URG4 expression and clinicopathologic parameters; we found that with the progression of NPC, the URG4 expression was upregulated gradually. This suggested that URG4 expression was significantly positively correlated with advancing clinical stage. We also found that there was a significant correlation between clinical stage, larger tumor size, and lymph node involvement. These suggested that URG4 was a biomarker of NPC progression. Univariate and multivariate Cox-regression analyses showed that patients with high URG4 expression had poor prognosis. These results emphasize that URG4 is a novel biomarker for NPC and it can be combined with other indentified biomarkers to choose appropriate therapy method, such as adjuvant chemotherapy, radiotherapy, or chemotherapy, and to predict the clinical stage and survival rate.
URG4 localization is different in different kinds of tumors. In ovarian cancer and HCC, URG4 mainly is expressed in cytoplasm, 4, 8 whereas in cervical cancer, URG4 
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URG4 as a novel prognostic factor for nPc mainly is found in plasma membrane. 7 We found that presence of URG4 in cytomembrane in NPC conditions facilitated clinical diagnosis.
Previous reports have shown that URG4 activates Akt and NF-κB pathway in HCC. 4, 6 Akt pathway 7 plays critical role in survival, glucose uptake, angiogenesis, proliferation, and metabolism. It inhibits Wee1, Myt1, p27, p21, and cyclin D1 and suppresses the progression of cell cycle. It also inhibits FOXO1, FOXO3a, and Bad, and meanwhile activates MDM2 to regulate apoptosis. 20 Akt has been demonstrated to regulate EMT in NPC.
2 NF-κB pathway regulates tumor cellular proliferation, apoptosis, angiogenesis, and metastasis. 21 Akt 2 and NF-κB pathway 22 regulate proliferation, metastasis, and apoptosis of NPC. There was a significant positive correlation between URG4 expression and clinical stage, larger tumor size, lymph node involvement, and distant metastasis, which suggested that URG4 might regulate proliferation and metastasis of NPC. We speculated that URG4 might regulate proliferation and metastasis through Akt pathway or NF-κB pathway. These findings suggested that URG4 might be a novel target for NPC therapy. But the role of URG4 in NPC should be studied in depth.
Conclusion
In conclusion, our study suggested that URG4 was upregulated in NPC tissues and its level showed a significant correlation with clinical stage, larger tumor size (T classification), and lymph node involvement (N classification). Patients with high URG4 level had poor outcome and URG4 was found to be an independent prognosis factor for NPC patients.
